{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:25:23Z","timestamp":1787840723358,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Varicella zoster virus is the etiologic agent of primary varicella (chickenpox) during childhood, and varicella vaccination has not been introduced in Iran. The aim of this study is to estimate cost-effectiveness of one- and two-dose Varicella Vaccination Program in Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A decision-tree model was conducted to evaluate the cost-effectiveness of the Varicella Vaccination Program in a cohort of 12 months children in Iran. Epidemiologic parameters of varicella were extracted from local and international sources, and cost of disease was estimated based on societal prospective in 2015 US$. Incremental cost per disability-adjusted life years (DALY) averted calculated as final outcome. Sensitivity analysis was also performed for lower and upper estimate of incidence, DALY, and vaccine efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Considering the vaccine efficacy of 95%, for the two-dose and 85% for the one-dose vaccination, incremental cost-effectiveness ratio (ICER) per DALYs averted were US$41,531 and US$17,280, respectively. ICER has changed between (US$ 6,177\u2013US$167,047) in lower and upper base estimate of epidemiological burden parameters in sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Varicella vaccination is not cost-effective in Iran in one-dose and two-dose scenario under the assumptions of this study in base case scenario according to the threshold of incremental cost per DALY averted less than three time of GDP per capita in Iran = US$ 14,292. One-dose vaccination program might be cost-effective in upper scenario of epidemiological burden of varicella in sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_295_16","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T08:17:08Z","timestamp":1512461828000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of Varicella Vaccination Program in Iran"],"prefix":"10.4103","volume":"8","author":[{"given":"Shooka","family":"Esmaeeli","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Yaghoubi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Nojomi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jcp.49.3.243","article-title":"Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections","volume":"49","author":"Nikkels","year":"1996","journal-title":"J Clin Pathol"},{"key":"R2-20250812","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(86)90556-8","article-title":"Fatal neonatal varicella infection","volume":"2","author":"Holland","year":"1986","journal-title":"Lancet"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.micro.50.1.59","article-title":"Live attenuated varicella vaccine","volume":"50","author":"Arvin","year":"1996","journal-title":"Annu Rev Microbiol"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1542\/peds.78.4.728","article-title":"Varicella: Complications and costs","volume":"78","author":"Preblud","year":"1986","journal-title":"Pediatrics"},{"key":"R5-20250812","first-page":"750","article-title":"Age-specific incidence of chickenpox","volume":"109","author":"Finger","year":"1994","journal-title":"Public Health Rep"},{"key":"R7-20250812","first-page":"95","article-title":"The seroepidemiology of varicella zoster virus (VZV) in different age groups in Tehran, Iran","volume":"4","author":"Sharifi","year":"2005","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/j.vaccine.2008.07.021","article-title":"Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil","volume":"26","author":"Valentim","year":"2008","journal-title":"Vaccine"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"R13-20250812","first-page":"43","article-title":"Seroprevalence of varicella-zoster virus in children from Shiraz-Iran","volume":"3","author":"Motamedifar","year":"2006","journal-title":"Iran J Immunol"},{"key":"R14-20250812","first-page":"372","article-title":"Varicella immunity in Iran: An age-stratified systematic review and meta-analysis","volume":"6","author":"Allami","year":"2014","journal-title":"Iran J Microbiol"},{"issue":"Suppl 2","key":"R15-20250812","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/522145","article-title":"Varicella vaccine effectiveness in the US vaccination program: A review","volume":"197","author":"Seward","year":"2008","journal-title":"J Infect Dis"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)12491-9","article-title":"Report of the WHO Commission on Macroeconomics and Health: a summary and critique","volume":"361","author":"Waitzkin","year":"2003","journal-title":"Lancet"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0264-410X(99)00261-3","article-title":"The cost-effectiveness of varicella vaccine programs for Australia","volume":"18","author":"Scuffham","year":"2000","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"R19-20250812","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1086\/522135","article-title":"An economic analysis of the universal varicella vaccination program in the United States","volume":"197","author":"Zhou","year":"2008","journal-title":"J Infect Dis"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01439446-201708000-00103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:43Z","timestamp":1787837263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01439446-201708000-00103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_295_16","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}